赛诺菲的 Dupixent 荨麻疹治疗药物在日本获得批准。 Sanofi's Dupixent Urticaria Treatment Approved in Japan.
荨麻疹，俗称荨麻疹，仍然是医学领域的一个令人烦恼的问题，其原因仍然难以捉摸。 Urticaria, commonly known as hives, remains a vexing problem in the medical field, with its causes remaining elusive. 然而，控制其症状通常很简单。 However, managing its symptoms is usually straightforward. 赛诺菲的 Dupixent 最近在日本获得批准用于治疗慢性自发性荨麻疹 (CSU)，使日本成为第一个这样做的国家。 Sanofi's Dupixent has recently been approved in Japan for treating chronic spontaneous urticaria (CSU), making Japan the first country to do so. Dupixent 是一种全人源单克隆抗体，可抑制参与 2 型炎症的关键蛋白信号传导，该蛋白在 CSU 中发挥作用。 Dupixent is a fully human monoclonal antibody that inhibits the signaling of key proteins involved in type 2 inflammation, which plays a role in CSU. 此次批准凸显了 Dupixent 作为一种针对这种疾病未满足需求的患者的新型治疗选择的价值，并且标志着该药物的第六个全球适应症。 This approval highlights Dupixent's value as a novel treatment option for patients with unmet needs in this condition, and it marks the sixth global indication for the drug.